Humasis Co

Humasis Co Payout Ratio

The Dividend Payout Ratio of Humasis Co (205470.KQ) as of Nov 9, 2026 is 5.27 %.

Payout Ratio

5.27 %

Last updated:

Dividend Payout Ratio of Humasis Co is 2021 5.27 % . Dividend Payout Ratio of Humasis Co was 2020 - . It decreases by % lower compared to the previous year.

The payout ratio is around 5% of earnings.

The Humasis Co Payout Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payout Ratio
Date
Payout Ratio
Jan 1, 2018
5.27 KRW
Jan 1, 2019
5.27 KRW
Jan 1, 2020
5.27 KRW
Jan 1, 2021
5.27 KRW
Jan 1, 2022
5.27 KRW
Jan 1, 2023
5.27 KRW
Jan 1, 2024
5.27 KRW
Jan 1, 2025
5.27 KRW
The Humasis Co Payout Ratio history
YEARPayout RatioYoY
5.27 %0.00%
5.27 %0.00%
5.27 %0.00%
5.27 %+0.00%
5.27 %-0.00%
5.27 %0.00%
5.27 %0.00%
5.27 %0.00%
5.27 %0.00%
5.27 %-0.00%
5.27 %0.00%
5.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Dividend Payout Ratio of Humasis Co is 5.27 % in 2021.

On Eulerpool you can find the complete historical development of Dividend Payout Ratio Humasis Co since 2006 – with annual values, charts, and detailed analysis.

The payout ratio measures the percentage of net income distributed as dividends. A sustainable payout ratio leaves room for reinvestment and growth.

Dividend Payout Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Payout Ratio's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Humasis Co

All Key Metrics — Humasis Co